Trial Profile
A Pilot Pharmacodynamic Study to Assess the Anti-proliferative Activity a of the Poly ADP Ribose Polymerase (PARP) Inhibitor Olaparib in Patients With Human Papilloma Virus (HPV) Positive and Human Papilloma Virus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 09 Jan 2020 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2018.
- 09 Jan 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.